Who
Herbert J. Conrad
Director
Company insider
Files Form 4 as: Director, Celldex Therapeutics; Director, Matinas Biopharma Holdings; Director, Arbutus Biopharma; Director, Pharmasset; Director, Savient Pharmaceuticals.
In numbers
- Trades disclosed
- 181
- Buys
- 2
- Sells
- 19
- Bought
- $154K
- Sold
- $5.5M
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 30 Dec 2005
- Last trade
- 25 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Jun 2026filed 29 Jun 2026 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —26,000 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —26,000 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —16,500 at $0.00 | filing |
| 13 Jun 2024filed 17 Jun 2024 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —16,500 at $0.00 | filing |
| 1 Nov 2023filed 3 Nov 2023 | MTNB Matinas Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —437,244 at $0.00 | filing |
| 15 Jun 2023filed 20 Jun 2023 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —11,300 at $0.00 | filing |
| 14 Nov 2022filed 16 Nov 2022 | MTNB Matinas Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —142,657 at $0.00 | filing |
| 22 Jun 2022filed 5 Jul 2022 | MTNB Matinas Biopharma HoldingsBiotechnology | SEC FORM 4 Code G | —1,358,122 at $0.00 | filing |
| 22 Jun 2022filed 5 Jul 2022 | MTNB Matinas Biopharma HoldingsBiotechnology | SEC FORM 4 Code G | —1,358,122 at $0.00 | filing |
| 16 Jun 2022filed 17 Jun 2022 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —13,600 at $0.00 | filing |
| 1 Nov 2021filed 2 Nov 2021 | MTNB Matinas Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,882 at $0.00 | filing |
| 4 Aug 2021filed 5 Jul 2022 | MTNB Matinas Biopharma HoldingsBiotechnology | SEC FORM 4 Code G | —494,622 at $0.00 | filing |
| 4 Aug 2021filed 5 Jul 2022 | MTNB Matinas Biopharma HoldingsBiotechnology | SEC FORM 4 Code G | —494,622 at $0.00 | filing |
| 7 Jul 2021filed 9 Jul 2021 | MTNB Matinas Biopharma HoldingsBiotechnology | SEC FORM 4 Code G | —1,280,917 at $0.00 | filing |
| 7 Jul 2021filed 9 Jul 2021 | MTNB Matinas Biopharma HoldingsBiotechnology | SEC FORM 4 Code G | —1,280,917 at $0.00 | filing |
| 19 Jun 2021filed 24 Jun 2021 | MTNB Matinas Biopharma HoldingsBiotechnology | SEC FORM 4 Code J | —40,000 at $0.00 | filing |
| 19 Jun 2021filed 24 Jun 2021 | MTNB Matinas Biopharma HoldingsBiotechnology | SEC FORM 4 Code C | —200,000 at $0.00 | filing |
| 19 Jun 2021filed 24 Jun 2021 | MTNB Matinas Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code C | —100 at $0.00 | filing |
| 17 Jun 2021filed 21 Jun 2021 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 20 May 2021filed 24 May 2021 | MTNB Matinas Biopharma HoldingsBiotechnology | SEC FORM 4 Code G | —1,145,905 at $0.00 | filing |
News
Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Shares Shorted: Short Interest Down 87.3% in SeptemberMTNB · dailypolitical.com · 12 Oct 2026
0 headlines in the last 90 days name Herbert J. Conrad; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.